Citi upgraded So-Young to Buy from Neutral with a price target of $3, up from 80c, following the "solid" Q4 results. Going into 2023, a gradual recovery of the platform business, driven by stronger demand for light medical aesthetic services and incremental revenue contribution from SY Prime, should maintain So-Young’s industry position as a leading vertical player, enable it to regain growth trajectory and achieve above-sector growth, the analyst tells investors in a research note.
Published first on TheFly